Botanix Reports 487% Revenue Growth as Sofdra Gains US Market Traction

Sofdra Drives Revenue Explosion in First Full US Commercial Year

Botanix Pharmaceuticals (ASX:BOT) has delivered a dramatic leap in revenue for the year ended 30 June 2026, reporting $33.8 million, up 487% from $5.8 million the previous year. This surge was powered primarily by the first full year of sales of Sofdra, the FDA-approved topical gel for excessive underarm sweating, in the United States. Royalty income from Japanese and South Korean licensees also contributed to the top line.

The commercial launch of Sofdra in February 2025 has catalysed rapid adoption among dermatologists, with total prescriptions shipped (TRx) soaring 527% year-on-year to 105,794. The fourth quarter alone saw a 145% increase in prescriptions compared to the same period last year, culminating in a record high monthly TRx of 12,895 in June 2026. The product's unique mechanism and patient-friendly applicator have been key drivers behind this uptake.

Losses Narrow Amid Strategic Investments and Cost Controls

Despite the revenue jump, Botanix recorded a net loss after tax of $69.8 million, an improvement of 19.25% from the $86.4 million loss in FY25. The reduction in losses reflects the balance between increased operating expenses; driven by investments in manufacturing inventory, an expanded sales force, the Botanix Fulfilment Platform, and accelerated marketing; and the significant growth in product revenues.

Botanix expanded its US sales team from 27 to 50 representatives during FY26 to support Sofdra's rollout. However, a post-year-end sales force realignment trimmed 11 territories, reallocating resources to the top-performing 39 territories responsible for 90% of prescriptions. This restructuring is expected to reduce operating costs by approximately 12% starting July 2026, enhancing profitability prospects.

Supply Chain Resilience and Intellectual Property Enhancements

Botanix has taken strategic steps to bolster its supply chain and intellectual property portfolio. The company renegotiated its API supply agreement with Kaken Pharmaceutical, deferring purchases originally due in April 2026 and January 2027 to December 2027 and beyond, easing near-term cash flow pressures.

In April 2026, Botanix signed a term sheet with Piramal for an alternate API supply, anticipated to reduce cost of goods sold by 25% to 40% and enhance manufacturing flexibility. Piramal’s US-based manufacturing is also strategically important to mitigate the impact of newly imposed US pharmaceutical tariffs, which will add an estimated $10 per bottle to Sofdra’s cost from September 2026.

On the intellectual property front, Botanix secured an Intention to Grant for a European patent protecting the Sofdra applicator, expected to extend exclusivity in key European markets until May 2039. Additionally, a US patent allowance for the crystalline form of Sofpironium Bromide promises protection until 2040, strengthening the product’s long-term commercial moat.

Capital Raising and Financial Position

To fuel ongoing growth and operational needs, Botanix completed a $45 million capital raise during FY26, including a placement and an underwritten security purchase plan. The funds are earmarked for API purchases, manufacturing, marketing, and working capital.

At year-end, the company held $36.6 million in cash, down from $65 million the prior year, with net cash outflows from operations of $64.6 million. The directors affirm the going concern basis, citing stable operating costs and confidence in future capital raising and revenue growth.

Commercial Platform and Market Opportunity

Botanix’s proprietary Fulfilment Platform has been a notable commercial asset, delivering a refill rate exceeding industry averages; patients receive over five fills annually compared to less than two for comparable topical treatments. This platform supports seamless prescription fulfillment, prior authorisation approvals, and improved gross-to-net yields, positioning Botanix well for future product launches and potential acquisition targets.

The US market for hyperhidrosis, affecting an estimated 10 million people, remains underserved, with only 3.7 million actively seeking treatment. Sofdra’s novel mechanism and safety profile have earned strong clinician endorsement, with 100% of surveyed healthcare providers intending to maintain or increase prescribing.

Leadership and Governance Updates

Botanix strengthened its executive team with the appointment of Paul Seaback as Chief Operating Officer, bringing over 30 years of biopharmaceutical industry experience. The board also welcomed Dr Patricia Walker as a non-executive director in August 2025, adding dermatology expertise to the governance team.

Remuneration practices have been reviewed following a shareholder vote against the previous year’s remuneration report. The board engaged extensively with shareholders and proxy advisers, committing to ongoing dialogue and alignment of executive incentives with company strategy and shareholder interests.

What to Watch Next

Botanix’s trajectory hinges on sustaining Sofdra’s prescription growth amid evolving US tariff regimes and supply chain adjustments. The successful onboarding of Piramal as a second API supplier and the granting of key patents will be critical to maintaining competitive advantage and margin improvement. Investors should also monitor the impact of the sales force realignment on operating costs and revenue momentum, as well as any strategic acquisition moves leveraging the Botanix Fulfilment Platform.

With a robust commercial infrastructure now in place, Botanix is at a pivotal juncture transitioning from a development-stage biotech to a revenue-generating pharmaceutical company. The balance between investment for growth and the path to profitability will shape its next chapter.